CN112858699B - Portable stress and mental illness objective index assessment test strip and method - Google Patents
Portable stress and mental illness objective index assessment test strip and method Download PDFInfo
- Publication number
- CN112858699B CN112858699B CN202110217787.7A CN202110217787A CN112858699B CN 112858699 B CN112858699 B CN 112858699B CN 202110217787 A CN202110217787 A CN 202110217787A CN 112858699 B CN112858699 B CN 112858699B
- Authority
- CN
- China
- Prior art keywords
- detection
- quality control
- glass cellulose
- probe
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000012360 testing method Methods 0.000 title claims abstract description 24
- 208000020016 psychiatric disease Diseases 0.000 title abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 126
- 239000000523 sample Substances 0.000 claims abstract description 89
- 238000003908 quality control method Methods 0.000 claims abstract description 48
- 239000002096 quantum dot Substances 0.000 claims abstract description 48
- 239000012528 membrane Substances 0.000 claims abstract description 43
- 229920002678 cellulose Polymers 0.000 claims abstract description 42
- 239000001913 cellulose Substances 0.000 claims abstract description 42
- 239000011521 glass Substances 0.000 claims abstract description 42
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 28
- 238000005507 spraying Methods 0.000 claims abstract description 21
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 16
- 238000004458 analytical method Methods 0.000 claims abstract description 9
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 80
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims description 52
- 229960000890 hydrocortisone Drugs 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 238000011156 evaluation Methods 0.000 claims description 18
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 10
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 7
- 239000011258 core-shell material Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 3
- 230000008859 change Effects 0.000 abstract description 7
- 238000004587 chromatography analysis Methods 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 3
- 238000007689 inspection Methods 0.000 abstract description 3
- 230000035882 stress Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 208000013200 Stress disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 206010015856 Extrasystoles Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005229 chemical vapour deposition Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明公开了便携式压力与精神疾病客观指标评估试纸条及方法，包括玻璃纤维素膜、硝酸纤维素膜、吸水纸、PVC板以及封闭盒盖；玻璃纤维素膜设置喷探针区域，喷探针区域喷涂不同规格量子点偶联探针和独立抗体探针，硝酸纤维素膜设质控线及检测线；在封闭盒盖的通孔滴加样本，通过检测分析装置在封闭盒盖的透明位置读取质控线和检测线的数据，根据量子点荧光强度和比值评估检测结果。本发明最短6分钟内即可完成多指标的检测，层析完成后10分钟之内检测浓度变化不超过10％，一小时内不超过15％，具有较好的时间稳定性，各指标关键区间定量检测CV在10％以内，检验操作简单，能满足基层以及社康较为繁忙情况下的检测精准度要求。
The present invention discloses a portable stress and mental illness objective index assessment test strip and method, including a glass cellulose membrane, a nitrocellulose membrane, a blotting paper, a PVC board and a closed box cover; the glass cellulose membrane is provided with a probe spraying area, the probe spraying area is sprayed with quantum dot coupled probes and independent antibody probes of different specifications, and the nitrocellulose membrane is provided with a quality control line and a detection line; the sample is dripped in the through hole of the closed box cover, and the data of the quality control line and the detection line are read at the transparent position of the closed box cover by a detection and analysis device, and the detection result is evaluated according to the fluorescence intensity and ratio of the quantum dots. The present invention can complete the detection of multiple indicators within 6 minutes at the shortest, and the detection concentration change does not exceed 10% within 10 minutes after the chromatography is completed, and does not exceed 15% within one hour, and has good time stability, and the quantitative detection CV of each indicator key interval is within 10%, and the inspection operation is simple, which can meet the detection accuracy requirements of the grassroots and the relatively busy community health.
Description
Technical Field
The invention relates to the field of in-vitro diagnosis, in particular to a portable pressure and mental disease objective index evaluation test strip and a using method thereof.
Background
Cortisol, also known as hydrocortisone, is a glucocorticoid extracted from the adrenal cortex and has a regulating effect on carbohydrate metabolism, and participates in regulating the daily rhythms of a human body, and in stress response and pressure regulation, endocrine and withdrawal homeostasis of the human body are maintained through a negative feedback mechanism of an HPA axis. The DHEA/DHEAS is a precursor small molecule of the cortisol, has correlation with the blood concentration of the cortisol, can be used for diagnosing endocrine dyscrasia related to stress and long-term pressure in a combined way, and is proved to have close relation with mental diseases related to anxiety, depression and the like by a large number of domestic and foreign researches. Compared with the traditional self-evaluation, he-evaluation and doctor inquiry, the blood or urine detection of the biomarker and the marker combination can greatly reduce the influence of subjective consciousness on the detection result, and overcome the common problems of insufficient professional doctors, medical resource shortage and the like in mental stress and disease diagnosis and general investigation.
At present, detection of cortisol and DHEA/DHEAS and other pressure regulating hormones is based on enzyme-linked immunosorbent assay (ELISA) detection kits (such as China patent CN102520165B and CN111351945A and partial marketed products), the operation is complex, and the reaction time is usually 6-24h. The detection kit has good detection sensitivity, however, the manual operation components are more, the experimental steps are more complicated, the reading equipment is more expensive, the detection precision and timeliness are difficult to ensure, and the detection kit has difficulties in transportation, preservation, application and popularization.
In the existing immunochromatography technology, the visual qualitative and semi-quantitative method based on colloidal gold is mature, the corresponding concentration of the detected protein can be estimated approximately by visually observing red detection strips (T lines), and the method has obvious advantages compared with ELISA methods in the aspects of detecting macromolecular proteins such as pregnancy and ovulation. However, for the hormone micromolecules related to the project, the colloidal gold immunochromatography technology cannot reach the clinically required detection sensitivity, and cannot accurately quantify, so that a stable detection result is obtained.
The quantum dot is a nano-scale semiconductor luminescent material, and the quantum dot is a core structure which is generally composed of elements of II-VI groups or III-V groups, and has the characteristics of high luminous intensity, good thermal stability, strong light-drift resistance and the like. The particle size, uniformity, core-shell structure composition and surface modification of the quantum dot material have obvious influence on the luminescence wavelength and the performance of the immunochromatography reagent.
Some studies use quantum dots with different particle diameters (light-emitting wavelengths) as marking materials for different detection indexes of multi-joint detection, and although the method has better effects in overcoming interference and improving detection accuracy, optical components in an immunofluorescence analyzer suitable for quantum dots with different light-emitting wavelengths are different, so that an ideal detection sensitivity and obvious distinction degree are achieved, a hardware optical module of equipment and software parameters are required to be matched, the volume and cost of the equipment are greatly increased, and the method is not suitable for portable mobile detection.
Accordingly, the present invention contemplates targeted improvements in view of the above-identified deficiencies of the prior art and the particular needs of use.
Disclosure of Invention
The technical problems to be solved by the invention are as follows: provides a portable pressure and mental disease objective index evaluation test strip and a using method thereof, so as to solve the technical and application problems of the prior methodology.
The technical scheme of the invention is as follows: the portable pressure and mental disease objective index evaluation test strip comprises a glass cellulose film, a nitrocellulose film, water absorbing paper, a PVC plate and a closed box cover;
the PVC plate is arranged in the closed box cover, the glass cellulose film, the nitrocellulose film and the water absorbing paper are arranged on the PVC plate, and two ends of the nitrocellulose film are respectively connected with the glass cellulose film and the water absorbing paper;
A spray probe area is arranged at one end of the glass cellulose membrane, which is close to the nitrocellulose membrane, and a coupling probe and an independent antibody probe are sprayed on the spray probe area, wherein the coupling probe is formed by coupling quantum dots with different specifications and the same wavelength with a specific antibody;
The nitrocellulose membrane is provided with a quality control line and at least one detection line in parallel, the quality control line is far away from the glass cellulose membrane, and the detection line is close to the glass cellulose membrane;
and the detection line is sprayed with an antigen combined with the detection specific probe, and the quality control line is sprayed with an independent antigen combined with the quality control independent antibody probe.
Preferably, the quantum dots are multi-specification CdSe/ZnS core-shell quantum dots with different polymerization degrees, and the luminescence wavelength is still generated by the core-shell quantum dots per se, and is hardly influenced by the polymerization degree.
Preferably, the specific antibody is a cortisol-specific antibody alone, a DHEA-specific antibody alone, a DHEAs-specific antibody alone, or one of cortisol and DHEA/DHEAs, together with the specific antibodies of the two indexes.
Preferably, the specific antibody comprises rabbit IgG monoclonal antibodies or mouse IgG monoclonal antibodies directed against the small molecule of interest.
Preferably, the detection line comprises T1 and T2, and the T1 and T2 are respectively sprayed with an antigen corresponding to a specific antibody.
Preferably, the independent antibody in the independent antibody quality control probe is DNP-BSA antibody, the quality control line is C, and the independent antigen is DNP-BSA antigen.
Preferably, the closed box cover comprises an upper cover and a lower cover, wherein a PVC plate is placed in the lower cover, the upper cover is provided with a through hole, and the through hole is positioned above one end, far away from the nitrocellulose membrane, of the glass cellulose membrane.
Preferably, the upper cover is provided with a transparent observation window, and the transparent observation window is positioned above the quality control line and the detection line.
The portable pressure and mental disease objective index evaluation method comprises the portable pressure and mental disease objective index evaluation test strip;
the method also comprises the following steps:
s1, spraying a detection specificity detection probe and an independent quality control antibody probe on a spraying probe area of one side of a glass cellulose membrane, which is close to a nitrocellulose membrane;
The detection specific antibody probes are probes formed by coupling quantum dots with different specifications and the same wavelength with specific antibodies, the specific antibodies are individual cortisol specific antibodies, individual DHEA specific antibodies, individual DHEAS specific antibodies, or one of cortisol and DHEA/DHEAS, and the two specific antibodies are combined;
the antibodies in the independent quality control antibody probes are DNP-BSA antibodies;
s2, arranging two detection lines and a quality control line on the nitrocellulose membrane, wherein the two detection lines are T1, T2 and C respectively, T1 is positioned between the glass cellulose membrane and T2, and T2 is positioned between T1 and C;
s3, spraying antigens corresponding to the detection specific antibody probes on the T1 and the T2; spraying DNP-BSA antigen corresponding to the DNP-BSA antibody on the C;
S4, mixing 5-20 ul of blood sample or urine sample with the diluent to form 60-80 ul of mixed solution, and dripping the mixed solution on the glass cellulose membrane at the position of the through hole of the upper cover;
s5, waiting for the reaction time to be 6-10 minutes;
s6, reading fluorescence data of the quality control line and the detection line position from the transparent observation window by using the detection analysis device, and according to the ratio of the fluorescence data of the detection line to the fluorescence data of the quality control line
And evaluating the detection results of the stress and the mental diseases.
By adopting the technical schemes, the multi-index detection can be completed within the shortest 6 minutes, the detection concentration change within 10 minutes after the chromatography is completed is not more than 10 percent, the detection concentration change within one hour is not more than 15 percent, and the time stability is good. The method has the advantages of low requirement on time accuracy of the read result, convenient use, simple operation and low cost, and can meet the detection accuracy requirement under the conditions of basic level and society health busyness.
Meanwhile, the invention combines the characteristics of high light intensity of quantum dot, long fluorescence lifetime and small particle size, can meet the requirement of low concentration compared with the conventional colloidal gold detection, particularly can meet the requirement of quantitative detection of cortisol or DHEA/DHEAS hormone micromolecule related to daily rhythm and pressure regulation by a competition method, can meet the requirement of reading a result by handheld equipment compared with an ELISA detection method, and can even observe and compare the brightness of fluorescent strips by using a UV light source of a banknote detector for preliminary analysis, thereby achieving the purposes of screening and evaluating pressure and mental diseases under different scenes.
Drawings
FIG. 1 is a schematic diagram of the structure of the present invention;
FIG. 2 is a schematic diagram showing stability of multiple sets of test data according to the present invention;
FIG. 3 is a schematic diagram of a detection result of a detection line according to the present invention;
fig. 4 is a schematic diagram of the detection results of two detection lines according to the present invention.
Reference numerals illustrate:
1. A glass cellulose film;
2. A probe spraying area;
3.A quantum dot;
4. Cortisol (DHEA/DHEAs) antibodies;
5. A blood sample or urine sample;
6. a nitrocellulose membrane;
7. cortisol (DHEA/DHEAs) antigen;
8. A detection line (T1);
9. A detection line (T2);
10. A quality control line (C);
11. DNP-BSA antigen;
12. A PVC plate;
13. a water absorbing paper;
14. a lower cover;
15. An upper cover;
16. A transparent viewing window;
17. DNP-BSA antibodies.
Detailed Description
The invention will be described in detail below with reference to the drawings and the specific embodiments.
Example 1
As shown in fig. 1, the present embodiment provides a portable test strip for evaluating objective indicators of stress and mental diseases, which comprises a glass cellulose film 1, a nitrocellulose film 6, a water absorbing paper 13, a PVC plate 12 and a closed box cover.
The PVC plate 12 is arranged in a closed box cover, the closed box cover comprises an upper cover 15 and a lower cover 14, and the PVC plate 12 is arranged at the bottom of the lower cover 14. The upper cover 15 is provided with a through hole for dripping a blood sample or a urine sample. The upper cover 15 is provided with a transparent observation window 16, and the transparent observation window 16 is positioned above the quality control line 10 and the detection line (8/9) and is used for the detection device to read signal data of the quality control line 10 and the detection line (8/9).
The glass cellulose film 1, the nitrocellulose film 6 and the water absorbing paper 13 are arranged on the PVC plate 12, and two ends of the nitrocellulose film 6 are respectively connected with the glass cellulose film 1 and the water absorbing paper 13.
The glass cellulose film 1 is provided with a spray probe region 2 near one end of the nitrocellulose film 6, and the other end of the glass cellulose film 1 is provided below the through hole as a sample end. The glass cellulose membrane is specially treated, and the height from the sample end to the probe spraying area 2 is gradually increased, so that blood cells of the whole blood sample can be effectively blocked on the glass cellulose membrane 1 after sample addition, and no signal and reaction interference are generated in the detection area. That is, the glass cellulose film 1 is subjected to the sealing treatment, and the right end is slightly higher than the left end, so that the stability and reliability of the test can be ensured.
The spray probe area 2 is sprayed with a detection specific antibody probe and an independent quality control antibody probe, wherein the detection probes are probes formed by coupling quantum dots 3 and specific antibodies 4 with different specifications and same wavelength.
The nitrocellulose membrane 6 is provided with a quality control line and at least one detection line in parallel, wherein the quality control line is far away from the glass cellulose membrane 1, and the detection line is close to the glass cellulose membrane 1.
And (3) spraying an antigen combined with a detection specific antibody probe on a detection line, and spraying an independent antigen combined with an independent quality control antibody probe on a quality control line.
The quantum dots 3 are multi-specification CdSe/ZnS core-shell quantum dots with different polymerization degrees, and the luminescence wavelength is still generated by the core-shell quantum dots per se, and is hardly influenced by the polymerization degree.
When the detection line adopts a T line, quantum dots 3 with the same specification and the same wavelength are selected.
When two detection lines, namely T1 (8) and T2 (9), are adopted, quantum dots 3 with different specifications and same wavelength are selected. The quantum dots with small specification are monodisperse quantum dots, and the quantum dots with large specification are polymeric quantum dots. The probe chromatographic speed of the marked monodisperse quantum dot is slightly faster than that of the probe marked by the polymeric quantum dot, the probe marked with the monodisperse quantum dot corresponds to a detection line T2 with a longer position, and the probe marked with the polymeric quantum dot corresponds to a detection line T1 with a shorter position. Different detection projects can finish the reaction within the same short time, so that mutual interference is reduced, all fluorescence results can be read by the same optical system, and errors caused by hardware differences are reduced.
Wherein, the specific antibody 4 is a cortisol-specific antibody alone, a DHEA-specific antibody alone, a DHEAS-specific antibody alone, or one of cortisol and DHEA/DHEAS, and the two antibodies are combined together (bigeminy detection). That is, in the case of the duplex assay, cortisol must be present in the specific antibody 4, which is used in combination with any one of DHEA/DHEAS.
Specific antibody 4 includes rabbit IgG monoclonal antibodies or mouse IgG monoclonal antibodies directed against the small molecule of interest.
T1 (8) and T2 (9) are sprayed with antigens corresponding to the specific antibodies, respectively. When the specific antibody 4 is a cortisol-specific antibody alone, only one T-line is required as cortisol-specific antigen 7. When the specific antibody is cortisol coupled with any one of DHEA/DHEAS, then T1 (8) and T2 (9) are at least one of cortisol antigen and DHEA/DHEAS antigen, respectively.
The antibody in the independent quality control antibody probe is DNP-BSA antibody 17, the quality control line is C (10), and the independent antigen is DNP-BSA antigen 11.
Example two
According to the structure of the first embodiment, the present embodiment is a portable stress and mental disease objective index evaluation method, including the portable stress and mental disease objective index evaluation test strip of the first embodiment. The test items of the test strip contain cortisol and DHEA/DHEAS hormone, and the estimated disease types include chronic stress, and mental diseases and endocrine disorders due to long-term stress and stimulus.
The method specifically comprises the following steps:
S1, spraying a coupling probe and an independent antibody probe on a probe spraying area 2 on one side of the glass cellulose membrane 1, which is close to the nitrocellulose membrane 6.
The conjugated probes are probes formed by coupling quantum dots with different specifications and the same wavelength with specific antibodies, and the specific antibodies are cortisol specific antibodies alone or DHEA specific antibodies alone or DHEAS specific antibodies alone or cortisol and one of DHEA/DHEAS (bigeminy detection).
The independent antibody in the independent antibody probe is DNP-BSA antibody.
S2, two detection lines and a quality control line are arranged on the nitrocellulose membrane 6, namely T1, T2 and C, wherein T1 is located between the glass cellulose membrane 1 and T2, and T2 is located between T1 and C.
S3, spraying antigens corresponding to the coupled probes on the T1 and the T2. And spraying DNP-BSA antigen corresponding to the DNP-BSA antibody on the C.
S4, mixing 5-20 ul of blood sample 5 with the diluent to form 60-80 ul of mixed solution, and dripping the mixed solution on the glass cellulose membrane 1 at the position of the through hole of the upper cover 15, wherein the urine sample can be directly added.
S5, waiting for the reaction time to be 6-10 minutes, wherein the concentration change of the reaction detected within 10 minutes after the chromatography is finished is not more than 10%, the concentration change within one hour is not more than 15%, the time stability is very good, the CV (chemical vapor deposition) of the same sample in a key detection interval is not more than 10%, and the biochemical reaction can be completed within a very short time and a relatively precise result can be achieved.
The reaction is that the mixed solution moves towards the direction of the absorbent paper 13: the small molecules to be detected in the blood sample or the urine sample 5 are firstly combined with the spray coupling probes and the independent antibody probes of the spray probe area 2 respectively, and then combined with the antigens on T1, T2 and C.
The reaction principle is as follows: because the related object to be detected is a small molecule, the concentration of the object to be detected is inversely proportional to the fluorescence intensity of the corresponding detection line quantum dots by using the competition method detection principle, the quantitative value is corrected by the ratio of the T line to the C line, and the sample type is corrected by the fixed parameter r of the crowd.
If a certain crowd or patient belongs to mental diseases such as high stress or anxiety, depression and the like, the secreted cortisol may be high, the fluorescence intensity of the corresponding T-line quantum dot is weaker, the fluorescence value of the C-line is not influenced by an object to be detected basically, the T/C value is smaller, and the higher cortisol concentration is converted. Meanwhile, the precursor DHEA/DHEAS hormone of the upstream cortisol of the crowd is lower, and the fluorescent intensity of the corresponding T-line quantum dots is higher, the T/C value is higher, and the concentration of the precursor DHEA/DHEAS is lower. The ratio of cortisol concentration to DHEA/DHEAs concentration (i.e., T Cortisol /TDHEA/DHEAS) for the same individual may be used to better assess the stress and mental condition of the individual.
And S6, reading fluorescence data of the positions of the quality control line and the detection line from the transparent observation window 16 by using a detection analysis device, calculating the concentration of cortisol and DHEA/DHEAS according to the ratio of the fluorescence data of the detection line to the fluorescence data of the quality control line, and evaluating the conditions of the stress and the mental diseases.
Applications of the method include, but are not limited to, detection of stress, stress-induced stress, endocrine dyscrasia, anxiety, depression, and the like, associated with the detection indicators selected by the present technology.
In step S6, the detection and analysis device used is an existing fluorescence data acquisition device, for example, a positioning base and a dark chamber with the patent number ZL201510120128.6 and an in-vitro detection and analysis device using the dark chamber, or a light source module with the patent number ZL 2015116072. X and an in-vitro detection and analysis device using the light source module, or a dark chamber with the patent number ZL 2015116173. X and an in-vitro detection and analysis device using the dark chamber.
Of course, according to the reaction principle in step S5, in the absence of a professional detection device, the brightness of fluorescence can be evaluated by an observed method. For example, the fluorescent values on the T line and the C line are irradiated through common daily necessities such as a UV light source or a banknote checking pen, and the mental condition of the person to be checked is evaluated through judging the brightness of the fluorescent values.
The quantum dots used in the invention can be excited by the same UV light source, the light emission color is red, the concentration of cortisol, DHEA/DHEAS and the concentration proportion relation among the cortisol, DHEA/DHEAS can be judged through the signal ratio of the detection line to the quality control line and the signal ratio (T1/C, T2/C, T1/T2) between the quality control lines after the reaction is finished, and a large number of domestic and foreign researches show that the values and the ratios have reference significance for the auxiliary diagnosis of the mental diseases caused by pressure and stress.
The detection principle is single detection or multi-detection by a small molecule competition method, and the T line has the highest signal value when no substance to be detected exists. Through adjusting T line department spraying antigen level, probe spraying proportion, independent C line fluorescence signal value, make each T line be in the fixed proportion of C line signal value when the material concentration that awaits measuring is in medical cut-off value (cutoff), be convenient for under the comparatively crude condition can be simple through preliminary judgement testing result of naked eye observation, provide help to this disease further detail inspection.
FIG. 2 is a graph showing the stability of cortisol probe and detection reagent at 25℃using quantum dot labeling. After the reaction is completed within 6 minutes after the blood sample is added, the portable immunofluorescence analyzer is used for first reading until 60 minutes. In total, 11 clinical samples are provided, each sample is a line, and the fact that each sample line fluctuates slightly, especially after 10 minutes, the time stability is good, and more accurate detection can be performed when accurate timing cannot be performed or the time is too busy can be seen.
As shown in FIG. 3, which is a schematic diagram of semi-quantitative concentration ratio, 22.5ug/dL is the upper limit of 95% of the clinical detection and judgment of reference chemiluminescent cortisol in the method, and the design can perform semi-quantitative judgment on fluorescent color through the brightness and width (basically about 1:1) of T line and C line under the concentration range of 20-23 ug/dL. The cortisol and DNEA/DHEAS in the detection project are small molecules, and are detected by adopting a competition method, so that the concentration of an object to be detected is higher as the fluorescent signal is smaller, namely the pressure is higher or the possibility of mental diseases such as anxiety, depression and the like are higher, therefore, the T line of the cortisol is narrow and the signal is weak, the T line width of the DHEA/DHEAS is strong, and the signal is strong (or through the comparison of the two detection lines) so as to prompt the need of further review and confirmation. Under the condition of the handheld portable equipment, the accurate quantitative reading and automatic counting are recommended to be carried out by using the handheld immunofluorescence analyzer.
As shown in FIG. 4, for multi-index joint inspection, two detection lines T1 and T2 are set, and the relation between cortisol and DHEA (DHEAS) detection values (with the units of ug/dL) and T1/T2 can be known. Where the respective concentrations are calculated in a manner r Tx/C, r is the conversion coefficient of the sample, determined by the different sample types, and serum is typically 1. T1/t2= (r×t1/C)/(r×t2/C), the ratio may be calculated in software by using the conversion result of the concentration standard curves of the two, and under severe conditions, the ratio may be estimated from the fluorescence intensities of the two bands (T1 and T2) and the band width. The clinical reference range of T1/T2 refers to the research results of more foreign cases, the ratio can reach more than or equal to 0.5 in pregnant women with anxiety disorder or high pressure, and the comparison group is less than or equal to 0.3, and the comparison group has obvious difference.
Compared with the prior art, the invention has the following technical effects:
The invention uses quantum dots with the same wavelength, but later prepares monodisperse quantum dots and multimeric quantum dots with the same wavelength but different dispersibility by polymerizing particles, and the monodisperse quantum dots and the multimeric quantum dots are respectively applied to probes of different detection targets.
The substances to be detected with smaller particle sizes and larger particle sizes are used for marking the substances to be detected with larger particle sizes and smaller particle sizes are marked with the detection lines by quantum dots, so that various indexes to be detected can be better distinguished in the chromatographic process, and the respective reaction precision and reaction speed are improved.
And an independent quality control line antigen-antibody probe is used, a quality control line signal is not influenced by a detection line, and the concentration of an object to be detected judges the ratio of a reference T line signal to a reference C line signal. The signal ratio of each substance to be detected also has diagnostic reference significance in the detection process of the substance to be detected related to mental diseases.
The test can be performed using blood (serum, plasma, whole blood, 20 ul) or urine samples, with a single or combined test of cortisol or DHEA/DHEAs. Blood cells in whole blood remain in the glass cellulose membrane 1 (the chromatography speed is extremely slow and the direction is slightly inclined in the opposite direction), and the quantum dot probe and the substance to be detected can rapidly complete chromatography without being influenced by the blood cells.
The multi-index detection can be completed within the shortest 6 minutes, the detection concentration change within 10 minutes after the chromatography is completed is not more than 10 percent, and the detection concentration change within one hour is not more than 15 percent, so that the method has better time stability. The method has the advantages of low requirement on time accuracy of the read result, convenient use, simple operation and low cost, and can meet the detection accuracy requirements of the basic level and the social health.
Meanwhile, the invention combines the characteristics of high light intensity of quantum dot, long fluorescence lifetime and small particle size, can meet the detection of low concentration and daily rhythmic pressure-related cortisol or DHEA/DHEAS hormone micromolecule compared with the conventional colloidal gold detection, can meet the reading result of handheld equipment compared with an ELISA detection method, and even can observe the effect of contrasting the brightness of fluorescent strips by using a UV light source of a banknote-detecting pen, thereby achieving the purposes of screening and evaluating mental diseases under different scenes.
The foregoing description of the preferred embodiment of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the invention.
Claims (8)
1. The portable pressure objective index evaluation test strip is characterized by comprising a glass cellulose film, a nitrocellulose film, water absorbing paper, a PVC plate and a closed box cover;
the PVC plate is arranged in the closed box cover, the glass cellulose film, the nitrocellulose film and the water absorbing paper are arranged on the PVC plate, and two ends of the nitrocellulose film are respectively connected with the glass cellulose film and the water absorbing paper;
A spray probe area is arranged at one end of the glass cellulose membrane, which is close to the nitrocellulose membrane, and is used for spraying a detection specific antibody probe and an independent quality control antibody probe, wherein the detection specific antibody probe is prepared by coupling quantum dots with different particle diameters and the same luminous wavelength with a specific antibody;
The nitrocellulose membrane is provided with a quality control line and two detection lines in parallel, the quality control line is far away from the glass cellulose membrane, the detection lines are close to the glass cellulose membrane, the detection lines are T1 and T2, antigens corresponding to detection specific antibodies are sprayed on the T1 and the T2 respectively, the quality control line is C, the T1 is positioned between the glass cellulose membrane and the T2, the T2 is positioned between the T1 and the C, the T2 with the far positions corresponding to quantum dot probes with small particle sizes is marked, and the T1 with the near positions corresponding to quantum dot probes with large particle sizes is marked;
the detection line is sprayed with an antigen combined with a detection specific probe, and the quality control line is sprayed with an independent quality control antigen combined with an independent quality control antibody probe;
one end of the glass cellulose membrane is lapped on the nitrocellulose membrane and is slightly higher than the other end of the glass cellulose membrane, and the glass cellulose membrane forms a slight inclination angle.
2. The portable pressure objective index evaluation test strip of claim 1, wherein the quantum dots are multi-particle size CdSe/ZnS core-shell quantum dots with different polymerization degrees.
3. The portable objective indicator evaluation test strip of claim 2, wherein the detection specific antibodies are a total of two specific antibodies, namely a cortisol specific antibody and a specific antibody of one of DHEA/DHEAs.
4. The portable pressure objective index evaluation test strip of claim 3, wherein the detection-specific antibody comprises rabbit IgG monoclonal antibody or mouse IgG monoclonal antibody directed against a small molecule of interest.
5. The portable pressure objective index evaluation test strip of claim 1, wherein the independent quality control antibody in the independent quality control antibody probe is a DNP-BSA antibody, and the independent quality control antigen is a DNP-BSA antigen.
6. The portable pressure objective index evaluation test strip of claim 1, wherein the closed box cover comprises an upper cover and a lower cover, the glass cellulose film, the nitrocellulose film, the water absorbing paper and the PVC plate are embedded into the lower cover as a whole, the upper cover is provided with a through hole, and the through hole is positioned above one end of the glass cellulose film far away from the nitrocellulose film.
7. The portable pressure objective index evaluation test strip of claim 6, wherein the upper cover is provided with a transparent viewing window, the transparent viewing window being located above the quality control line and the detection line.
8. The portable pressure objective index evaluation method is a method for non-disease diagnosis, and is characterized by comprising the portable pressure objective index evaluation test strip according to any one of claims 1-7;
the method also comprises the following steps:
S1, spraying a specific antibody probe and an independent quality control antibody probe on a probe spraying area of one side of a glass cellulose membrane, which is close to a nitrocellulose membrane;
the detection specific antibody probe is prepared by coupling quantum dots with different particle sizes and the same luminous wavelength with specific antibodies, and the detection specific antibodies are a combined detection combination consisting of two specific antibodies in total of cortisol specific antibodies and specific antibodies of one of DHEA/DHEAS;
the antibodies in the independent quality control antibody probes are DNP-BSA antibodies;
s2, arranging two detection lines and a quality control line on the nitrocellulose membrane, wherein the two detection lines are T1, T2 and C respectively, T1 is positioned between the glass cellulose membrane and T2, and T2 is positioned between T1 and C;
s3, spraying antigens corresponding to the detection specific probes on the T1 and the T2; spraying DNP-BSA antigens corresponding to the quality control DNP-BSA antibody probes on the C;
s4, mixing 5-20 ul of blood sample or urine sample with the diluent, and dripping 60-80 ul of mixed solution on the glass cellulose membrane under the position of the through hole of the upper cover of the closed box cover;
S5, waiting for the reaction time to be 6-10 minutes;
And S6, reading fluorescence data of the positions of the quality control line and the detection line from a transparent observation window of the upper cover of the closed box cover by using a detection analysis device, calculating the concentration of cortisol, DHEA/DHEAS according to the ratio of the fluorescence data of the detection line to the fluorescence data of the quality control line, and evaluating the pressure condition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110217787.7A CN112858699B (en) | 2021-02-26 | 2021-02-26 | Portable stress and mental illness objective index assessment test strip and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110217787.7A CN112858699B (en) | 2021-02-26 | 2021-02-26 | Portable stress and mental illness objective index assessment test strip and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112858699A CN112858699A (en) | 2021-05-28 |
| CN112858699B true CN112858699B (en) | 2024-11-22 |
Family
ID=75990257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110217787.7A Active CN112858699B (en) | 2021-02-26 | 2021-02-26 | Portable stress and mental illness objective index assessment test strip and method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112858699B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113466448A (en) * | 2021-06-30 | 2021-10-01 | 广东牧玛生命科技有限公司 | Placental protein 13 test strip and quantitative detection method |
| CN114264815A (en) * | 2021-12-13 | 2022-04-01 | 深圳容金科技有限公司 | Quantum dot immunoassay kit and detection method for clenbuterol content |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2356059C1 (en) * | 2007-11-19 | 2009-05-20 | Государственное учреждение Научно-исследовательский институт психического здоровья Томского научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ ПЗ ТНЦ СО РАМН) | Method of prognosis of clinic course of neurotic disorders |
| CN102520165A (en) * | 2011-12-29 | 2012-06-27 | 北京康美天鸿生物科技有限公司 | Method for highly sensitive quantitative detection of quantum dot fluorescence immunochromatographic assay |
| KR20140019547A (en) * | 2012-08-06 | 2014-02-17 | 주식회사 피코팜 | A mesurement method of stress by figuring stress |
| CN107667290A (en) * | 2015-04-06 | 2018-02-06 | Blu诊断有限公司 | For detecting the detection means and application method of the analyte in saliva sample |
| CN110007076A (en) * | 2019-05-13 | 2019-07-12 | 无锡博慧斯生物医药科技有限公司 | A whole blood sample detection device and detection method thereof |
| CN214427452U (en) * | 2021-02-26 | 2021-10-19 | 深圳量点科技有限公司 | Portable Test Strips for Objective Indicators of Stress and Mental Illness |
-
2021
- 2021-02-26 CN CN202110217787.7A patent/CN112858699B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2356059C1 (en) * | 2007-11-19 | 2009-05-20 | Государственное учреждение Научно-исследовательский институт психического здоровья Томского научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ ПЗ ТНЦ СО РАМН) | Method of prognosis of clinic course of neurotic disorders |
| CN102520165A (en) * | 2011-12-29 | 2012-06-27 | 北京康美天鸿生物科技有限公司 | Method for highly sensitive quantitative detection of quantum dot fluorescence immunochromatographic assay |
| KR20140019547A (en) * | 2012-08-06 | 2014-02-17 | 주식회사 피코팜 | A mesurement method of stress by figuring stress |
| CN107667290A (en) * | 2015-04-06 | 2018-02-06 | Blu诊断有限公司 | For detecting the detection means and application method of the analyte in saliva sample |
| CN110007076A (en) * | 2019-05-13 | 2019-07-12 | 无锡博慧斯生物医药科技有限公司 | A whole blood sample detection device and detection method thereof |
| CN214427452U (en) * | 2021-02-26 | 2021-10-19 | 深圳量点科技有限公司 | Portable Test Strips for Objective Indicators of Stress and Mental Illness |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112858699A (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McClelland et al. | A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification | |
| CN108195815A (en) | Time-resolved fluoroimmunoassay chromatography detects test strips, kit and the method for AMH | |
| CN207248894U (en) | Bladder chalone C time resolution detection card and kit | |
| CN112858699B (en) | Portable stress and mental illness objective index assessment test strip and method | |
| CN107121548A (en) | Quantitatively detect test paper, preparation method and the detection method of tumor markers | |
| CN214427452U (en) | Portable Test Strips for Objective Indicators of Stress and Mental Illness | |
| EP1802977A2 (en) | Test device for the in vitro diagnosis of multi-analyse tests and the use thereof | |
| US20110118141A1 (en) | Disease Specific Diagnostic Aid | |
| CN107656048A (en) | A kind of immuno-chromatographic test paper strip and its application of half-quantitative detection antigen or antibody | |
| US20180306815A1 (en) | Lateral flow assay ratio test | |
| Yin et al. | Measurement differences between two immunoassay systems for LH and FSH: a comparison of roche cobas e601 vs. Abbott Architect i2000sr | |
| CN107907694A (en) | Anti- mullerian duct hormone test kit and preparation method thereof | |
| CN101477059A (en) | Method for rapidly detecting inorganic phosphorus in water solution | |
| CN210323044U (en) | IL-6/PCT combined detection time resolution detection card and kit | |
| CN111579801A (en) | Single-dose kit for detecting anti-mullerian hormone content and detection method thereof | |
| CN207396501U (en) | A kind of immuno-chromatographic test paper strip of half-quantitative detection antigen or antibody | |
| JP2021511525A (en) | Multiplex lateral flow assay to distinguish between viral and bacterial infections | |
| US20140011190A1 (en) | Method for performing a rapid test | |
| CN114814243B (en) | Quantitative detection kit and method applied to protein antigen | |
| CN207976394U (en) | Time-resolved fluoroimmunoassay chromatography detects the test strips and kit of AMH | |
| Buck et al. | Various methods for determining urinary choriogonadotropin evaluated for the early diagnosis of ectopic pregnancy. | |
| Zhang et al. | A new method for broadening the detection range of immunoassay and its application in β-hCG quantitative detection | |
| JP3481894B2 (en) | Measurement method using immunological chromatographic method | |
| CN2442271Y (en) | Multiple level test strip for urine HCG | |
| CN108459167A (en) | A kind of kit and preparation method thereof quantitatively detected for β-HCG, PDG in human urine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210927 Address after: 518000 room a, 11th floor, block a, phase II, high tech park, guangqiao Road, Tianliao community, Yutang street, Guangming District, Shenzhen City, Guangdong Province Applicant after: SHENZHEN LIANGDIAN TECHNOLOGY Co.,Ltd. Applicant after: SHENZHEN University Address before: 518000 room a, 11th floor, block a, phase II, high tech park, guangqiao Road, Tianliao community, Yutang street, Guangming District, Shenzhen City, Guangdong Province Applicant before: SHENZHEN LIANGDIAN TECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |